RT Book, Section
A1 Brahm, Nancy C.
A1 Erickson, Steven R.
A1 Stewart, Douglas W.
A2 DiPiro, Joseph T.
A2 Talbert, Robert L.
A2 Yee, Gary C.
A2 Matzke, Gary R.
A2 Wells, Barbara G.
A2 Posey, L. Michael
SR Print(0)
ID 1145195922
T1 Disorders Associated with Intellectual Disabilities
T2 Pharmacotherapy: A Pathophysiologic Approach, 10e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259587481
LK accesspharmacy.mhmedical.com/content.aspx?aid=1145195922
RD 2024/04/19
AB KEY  CONCEPTS  Persons  diagnosed  with  Down  syndrome  (DS)  can  be  at  increased  risk  for  medical  and  psychiatric  comorbidities.  In  persons  with  DS,  a  thorough  evaluation  is  needed  to  differentiate  between  depression  and  Alzheimer  disease.  Treatment  plans  for  persons  with  autism  spectrum  disorder  (ASD)  focus  on  increasing  social  interactions,  improving  verbal  and  nonverbal  communication,  and  minimizing  the  occurrence  or  impact  of  ritualistic,  repetitive  behaviors  and  other  related  mood  and  behavioral  problems  (eg,  overactivity,  irritability,  and  self-injury).  Many  purported  pharmacologic  and  nonpharmacologic  treatments  for  ASD  lack  objective  evidence-based  support.  A  structured  teaching  approach  focusing  on  increasing  social  communication  and  integration  with  peers  is  needed  when  providing  services  to  persons  with  ASD.  Nonpharmacologic  interventions  for  sleep  disturbances  in  children  with  a  diagnosis  of  ASD  should  be  implemented  prior  to  pharmacotherapy  considerations.  Psychopharmacologic  treatment  planning  should  include  monitoring  of  objective,  measurable,  medication-responsive  target  behaviors,  and  assessment  of  potential  adverse  effects  is  of  critical  importance  when  treating  behavioral  symptoms  of  ASD,  as  the  response  of  individuals  to  medication  therapy  is  highly  variable.  The  use  of  Food  and  Drug  Administration-approved  medication  for  off-label  indications  is  an  acceptable  clinical  practice  if  founded  on  evidence-based  research  and  informed  consent.  The  level  of  impairment  in  Rett  syndrome  (RTT)  is  increasingly  associated  with  the  particular  genetic  mutation  involved.